Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007–2008)

References 

1. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl. 5):S344–S349
   • CrossRef
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317
   • CrossRef
3. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents. 2003;22:406–419
   • Abstract
   • Full Text
   • Full-Text PDF (236 KB)
   • CrossRef
4. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373–1406
   • CrossRef
5. Hope R, Livermore DM, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001–06. J Antimicrob Chemother. 2008;62(Suppl. 2):ii65–ii74
   • CrossRef
6. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004–05 Prospective European Surveillance Initiative. J Antimicrob Chemother. 2008;62:116–121
   • CrossRef
7. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52:2383–2388
   • CrossRef
8. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl. 5):S378–S385
   • CrossRef
9. VIBATIV™ (telavancin) for injection (package insert). Theravance, Inc. and Astellas Pharma Global Development, Inc. http://www.vibativ.com [accessed 28 May 2010].
10. Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother. 2009;53:3375–3383
    • CrossRef
11. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M07-A8. Wayne, PA: CLSI; 2009.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.
13. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical MIC breakpoints. http://www.eucast.org/clinical_breakpoints [accessed 1 June 2010].
14. Rubenstein E, Corey GR, Stryjewski ME. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies. In: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 19–22 April 2008, Barcelona, Spain. Basel, Switzerland: ESCMID; 2008;[Abstract O15]